- Home
- DBI vs AUTL Comparison
DBI vs AUTL Comparison
Compare DBI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBI | AUTL |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.2M | 431.2M |
| IPO Year | 2005 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DBI | AUTL |
|---|---|---|
| Price | $5.29 | $1.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.75 | ★ $8.50 |
| AVG Volume (30 Days) | 521.6K | ★ 1.4M |
| Earning Date | 03-26-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 28.33 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $3,009,262,000.00 | $10,120,000.00 |
| Revenue This Year | N/A | $669.62 |
| Revenue Next Year | $2.87 | $79.78 |
| P/E Ratio | $23.39 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $2.18 | $1.11 |
| 52 Week High | $8.75 | $2.70 |
Technical Indicators
Market Signals| Indicator | DBI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 33.07 | 37.41 |
| Support Level | $3.24 | $1.27 |
| Resistance Level | $8.24 | $1.52 |
| Average True Range (ATR) | 0.39 | 0.08 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 5.00 | 1.47 |
Price Performance
Historical ComparisonAbout DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.